[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hyperactive-masseter-muscle\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hyperactive-masseter-muscle":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":5},"100613703","evaluation-the-efficacy-of-zinc-on-botulinum-toxin-a-injection-100613703",false,"NCT07270042","Evaluation the Efficacy of Zinc on Botulinum Toxin A Injection","Evaluation of the Efficacy of Zinc on the Duration and Effictiveness of Botulinum Toxin A Injection in the Context of Hyperactive Masseter Muscle (A Prospective Clinical Study)","BTX-A","Inclusion Criteria:\n\nParticipants will be adults aged 18-60 years presenting with clinically confirmed masseteric hypertrophy or hyperactivity, as approved by EMG.\n\nExclusion Criteria:\n\n* Pregnancy or lactation;\n* Patients have aminoglycosides or vit B12.\n* Prior BTX-A treatment to the masseter within the previous 12 months;\n* Neuromuscular disorders or hypersensitivity to BTX-A or zinc compounds;\n* Systemic illness affecting zinc metabolism (e.g., hepatic, renal, or metabolic disorders);\n* Active infection, inflammation, or cutaneous lesions at the injection site.",true,"ALL","18 Years","60 Years",{"count":22,"type":23},20,"ESTIMATED","INTERVENTIONAL",[26],"NA","This clinical trial seeks to investigate a promising new approach to enhance the effectiveness and duration of Botulinum Toxin A (BTX-A) for the treatment of hyperactive masseter muscles. By investigating the role of oral zinc supplementation, this study could provide a cost-effective, sustainable solution for patients suffering from both aesthetic concerns and functional limitations associated with MMH and bruxism. The findings of this study will expand the clinical applications of BTX-A, offering longer-lasting relief and reducing the need for frequent injections, which could revolutionize the management of MMH in clinical practice.",[29],"Hyperactive Masseter Muscle",[31,32,33,34],"Masseter Muscle","Botulinum Toxin","zinc","electromyographic (EMG)","NOT_YET_RECRUITING","2025-11-25",{"date":38,"type":39},"2025-12-08","ACTUAL",{"date":41,"type":23},"2025-12-01",{"date":43,"type":23},"2026-12-01",{"name":45,"class":46},"Tishreen University","OTHER"]